Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Losmapimod for Proteinuria in FSGS
NCT02000440Phase 2Completed
- Sponsor
- GSK
- Start
- Jul 2014
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of losmapimod in focal segmental glomerulosclerosis (FSGS), sponsored by GSK. Primary endpoint: Number of Participants Meeting the Definition of Responder for Reduction in Proteinuria at Week 24. Started Jul 2014; status: completed.
02
Drugs
losmapimod
03
Conditions
focal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on NCT02000440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02000440.